Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. uri icon

authors

  • Shannon R. McCurdy, MD
  • Brodsky, Robert A
  • Ambinder, Richard F
  • Bettinotti, Maria P
  • Fuchs, Ephraim J
  • Rosner, Gary L
  • Jones, Richard J
  • Luznik, Leo
  • Kanakry, Christopher G
  • Tsai, Hua-Ling
  • Kasamon, Yvette L
  • Showel, Margaret M
  • Bolaños-Meade, Javier
  • Huff, Carol Ann
  • Borrello, Ivan
  • Matsui, William H

publication date

  • October 18, 2017